{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:23:20Z","timestamp":1787261000457,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018430","name":"Fondazione Istituto Europeo di Oncologia e Centro Cardiologico Monzino","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018430","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018429","name":"Istituto Europeo di Oncologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctro.2026.101239","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:12:31Z","timestamp":1784304751000},"page":"101239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An overlooked opportunity? SBRT + ADT for aggressive prostate cancer in the elderly"],"prefix":"10.1016","volume":"60","author":[{"given":"Chiara","family":"Lorubbio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Repetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mastroleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giulia","family":"Vincini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Netti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luzzago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Alessandro","family":"Mistretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Counago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon K.B.","family":"Spohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Petralia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Musi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavio","family":"De Cobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Orecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marvaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2026.101239_bb0005","author":"NCCN"},{"issue":"10","key":"10.1016\/j.ctro.2026.101239_bb0010","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(14)70361-4","article-title":"Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial","volume":"15","author":"Lane","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctro.2026.101239_bb0015","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101239_bb0020","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate Cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2 = 1.4 (0.9\u20132.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"issue":"4","key":"10.1016\/j.ctro.2026.101239_bb0025","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijrobp.2019.07.027","article-title":"Comparison of outcomes and toxicity between extreme and moderate radiation therapy Hypofractionation in localized prostate Cancer: a propensity score analysis","volume":"105","author":"Marvaso","year":"2019","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"issue":"15","key":"10.1016\/j.ctro.2026.101239_bb0030","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2010.31.4377","article-title":"Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate Cancer","volume":"29","author":"Boike","year":"2011","journal-title":"JCO"},{"key":"10.1016\/j.ctro.2026.101239_bb0035","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160725","article-title":"Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of phase II trial AIRC-IG-13218","author":"Timon","year":"2018","journal-title":"BJR"},{"issue":"4","key":"10.1016\/j.ctro.2026.101239_bb0040","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate Cancer: a systematic review and Meta-analysis of over 6,000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"10.1016\/j.ctro.2026.101239_bb0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ctrv.2016.08.005","article-title":"Extreme hypofractionation for early prostate cancer: biology meets technology","volume":"50","author":"De Bari","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"10.1016\/j.ctro.2026.101239_bb0050","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2026.101239_bb0055","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fonc.2014.00301","article-title":"Quality of life and toxicity after SBRT for organ-confined prostate Cancer, a 7-year study","volume":"4","author":"Katz","year":"2014","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.ctro.2026.101239_bb0060","article-title":"Stereotactic body radiotherapy for low-risk prostate Cancer: a ten-year analysis","volume":"9","author":"Katz","year":"2017","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.ctro.2026.101239_bb0065","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5306\/wjco.v8.i5.389","article-title":"Stereotactic radiotherapy for prostate cancer: a review and future directions","volume":"8","author":"Syed","year":"2017","journal-title":"World J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2026.101239_bb0070","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101239_bb0075","article-title":"Management of Prostate Cancer in older adults","volume":"43","author":"Graham","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"10.1016\/j.ctro.2026.101239_bb0080","doi-asserted-by":"crossref","first-page":"709","DOI":"10.7326\/0003-4819-158-10-201305210-00005","article-title":"Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population\u2013based cohort of men with prostate Cancer","volume":"158","author":"Daskivich","year":"2013","journal-title":"Ann Intern Med"},{"issue":"10196","key":"10.1016\/j.ctro.2026.101239_bb0085","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ctro.2026.101239_bb0090","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate Cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"JCO"},{"issue":"7","key":"10.1016\/j.ctro.2026.101239_bb0095","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(25)00205-0","article-title":"Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial","volume":"26","author":"Tree","year":"2025","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2026.101239_bb0100","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2018.01.016","article-title":"The efficacy and safety of conventional and Hypofractionated high-dose radiation therapy for prostate Cancer in an elderly population: a subgroup analysis of the CHHiP trial","volume":"100","author":"Wilson","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2026.101239_bb0105","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-024-04876-8","article-title":"Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial \u201cGIVE ME FIVE.\u201d","volume":"42","author":"Marvaso","year":"2024","journal-title":"World J Urol"},{"issue":"15","key":"10.1016\/j.ctro.2026.101239_bb0110","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate Cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2026.101239_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-025-00962-z","article-title":"Hypofractionated radiotherapy in elderly patients (\u226575 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study","author":"Ingrosso","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.ctro.2026.101239_bb0120","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11547-023-01618-5","article-title":"Extreme hypofractionated stereotactic radiotherapy for elderly prostate cancer patients: side effects preliminary analysis of a phase II trial","volume":"128","author":"Gregucci","year":"2023","journal-title":"Radiol Med"},{"key":"10.1016\/j.ctro.2026.101239_bb0125","doi-asserted-by":"crossref","first-page":"S2645","DOI":"10.1016\/S0167-8140(24)03365-6","article-title":"3395: acute toxicity from PACE-C comparing stereotactic body radiotherapy (SBRT) with moderate hypofractionation (MHRT)","volume":"194","author":"Tree","year":"2024","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2026.101239_bb0130","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12032-018-1155-y","article-title":"\u201cGive me five\u201d ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach","volume":"35","author":"Marvaso","year":"2018","journal-title":"Med Oncol"},{"issue":"8","key":"10.1016\/j.ctro.2026.101239_bb0135","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-020-01397-3","article-title":"Phase II prospective trial \u201cGive me five\u201d short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218)","volume":"37","author":"Marvaso","year":"2020","journal-title":"Med Oncol"},{"issue":"7","key":"10.1016\/j.ctro.2026.101239_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072296","article-title":"Potential risk of other-cause mortality due to long-term androgen deprivation therapy in elderly patients with clinically localized prostate cancer treated with radiotherapy\u2014a confirmation study","volume":"9","author":"Yamazaki","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ctro.2026.101239_bb0145","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamainternmed.2024.5994","article-title":"Overtreatment of prostate Cancer among men with limited longevity in the active surveillance era","volume":"185","author":"Daskivich","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.ctro.2026.101239_bb0150","first-page":"476","article-title":"Intensity-modulated radiation therapy for elderly patients (aged \u226575 years) with localized prostate cancer: comparison with younger patients (aged <75 years)","volume":"10","author":"Tanaka","year":"2019","journal-title":"Mol Clin Oncol"},{"issue":"2B","key":"10.1016\/j.ctro.2026.101239_bb0155","first-page":"1319","article-title":"Influence of age on the pattern and outcome of external beam radiotherapy for clinically localized prostate cancer","volume":"26","author":"Ogawa","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctro.2026.101239_bb0160","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:23:31Z","timestamp":1787257411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826001345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"alternative-id":["S2405630826001345"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101239","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overlooked opportunity? SBRT + ADT for aggressive prostate cancer in the elderly","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101239"}}